Aileron Therapeutics secures new financing

Aileron Therapeutics has secured $30 million in Series E equity financing from investors including Apple Tree Partners, Roche Venture Fund, Novartis Venture Funds, Lilly Ventures, SR One and Excel Venture Management. The clinical stage biopharmaceutical company is developing therapeutics based on its proprietary Stapled Peptide drug platform.

North AmericaUSBriefs